Editorial: Theranostics as a driving force in nuclear medicine.
作者信息
Rowe Steven P, Werner Rudolf A, Ray Banerjee Sangeeta
机构信息
Molecular Imaging and Therapeutics, Department of Radiology, University of North Carolina, Chapel Hill, NC, United States.
Clinic for Radiology and Nuclear Medicine, Division of Nuclear Medicine, Goethe University, Frankfurt, Germany.
出版信息
Front Oncol. 2024 Sep 6;14:1468357. doi: 10.3389/fonc.2024.1468357. eCollection 2024.
Abstract
摘要
相似文献
1
Editorial: Theranostics as a driving force in nuclear medicine.社论：治疗诊断学作为核医学的驱动力。
Front Oncol. 2024 Sep 6;14:1468357. doi: 10.3389/fonc.2024.1468357. eCollection 2024.
2
Synthesis of DOTA-Based Sc Radiopharmaceuticals Using Cyclotron-Produced Sc as Exemplified by [Sc]Sc-PSMA-617 for PSMA PET Imaging.使用回旋加速器生产的钪合成基于DOTA的钪放射性药物，以用于PSMA PET成像的[钪]钪-PSMA-617为例。
Methods Protoc. 2025 Jun 4;8(3):58. doi: 10.3390/mps8030058.
3
FAP and PSMA Expression by Immunohistochemistry and PET Imaging in Castration-Resistant Prostate Cancer: A Translational Pilot Study.去势抵抗性前列腺癌中免疫组织化学和PET成像检测FAP和PSMA表达：一项转化性初步研究
J Nucl Med. 2024 Dec 3;65(12):1952-1958. doi: 10.2967/jnumed.124.268037.
4
Immunohistochemical basis for FAP as a candidate theranostic target across a broad range of cholangiocarcinoma subtypes.FAP作为广泛胆管癌亚型潜在治疗诊断靶点的免疫组化基础。
Front Nucl Med. 2024 Nov 27;4:1480471. doi: 10.3389/fnume.2024.1480471. eCollection 2024.
5
Dual Targeting of Prostate-Specific Membrane Antigen and Fibroblast Activation Protein: Bridging Prostate Cancer Theranostics with Precision.前列腺特异性膜抗原和成纤维细胞活化蛋白的双重靶向：精准连接前列腺癌诊疗
ACS Appl Bio Mater. 2025 Feb 17;8(2):962-979. doi: 10.1021/acsabm.4c01914. Epub 2025 Feb 3.
6
Prostate-Specific Membrane Antigen as Target for Neuroimaging of Central Nervous System Tumors.前列腺特异性膜抗原作为中枢神经系统肿瘤神经影像学的靶点。
Mol Imaging. 2022 Apr 15;2022:5358545. doi: 10.1155/2022/5358545. eCollection 2022.
7
Evaluation of Lu and Sc Picaga-Linked, Prostate-Specific Membrane Antigen-Targeting Constructs for Their Radiotherapeutic Efficacy and Dosimetry.Lu 和 Sc 双载前列腺特异性膜抗原靶向构建物的放射治疗疗效和剂量学评价。
Mol Pharm. 2021 Dec 6;18(12):4511-4519. doi: 10.1021/acs.molpharmaceut.1c00711. Epub 2021 Oct 29.
8
A Case Report on the Dramatic Response of Lu-PSMA Therapy for Metastatic Prostate Cancer.一例关于镥-PSMA疗法对转移性前列腺癌显著疗效的病例报告。
Curr Med Imaging. 2025;21:e15734056362468. doi: 10.2174/0115734056362468250709045212.
9
Synthesis of Ac-PSMA-617 for Preclinical Use.用于临床前研究的Ac-PSMA-617的合成。
Curr Radiopharm. 2022;15(2):96-103. doi: 10.2174/1874471014666210709094616.
10
Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine.治疗学：利用分子成像和治疗来影响患者管理并确保核医学的未来。
J Nucl Med. 2020 Mar;61(3):311-318. doi: 10.2967/jnumed.118.220665. Epub 2020 Jan 10.
本文引用的文献
1
Comparison of Nuclear Medicine Therapeutics Targeting PSMA among Alpha-Emitting Nuclides.比较 PSMA 靶向 α 发射核素的核医学治疗。
Int J Mol Sci. 2024 Jan 11;25(2):933. doi: 10.3390/ijms25020933.
2
3BP-3940, a highly potent FAP-targeting peptide for theranostics - production, validation and first in human experience with Ga-68 and Lu-177.3BP-3940，一种用于诊疗的高效靶向成纤维细胞活化蛋白（FAP）的肽——生产、验证及首例使用镓-68和镥-177的人体试验经验
iScience. 2023 Nov 23;26(12):108541. doi: 10.1016/j.isci.2023.108541. eCollection 2023 Dec 15.
3
At the right dose: personalised (N-of-1) dosing for precision oncology.精准医学中的右剂量：个体化（N-of-1）剂量。
Eur J Cancer. 2023 Nov;194:113359. doi: 10.1016/j.ejca.2023.113359. Epub 2023 Sep 24.
4
Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer.前列腺癌放射性药物治疗的临床前开发。
Semin Nucl Med. 2023 Sep;53(5):663-686. doi: 10.1053/j.semnuclmed.2023.06.007. Epub 2023 Jul 18.
5
Birth of the Beta-knife Thyroidectomy: The Radiance of Saul Hertz.贝塔刀甲状腺切除术的诞生：索尔·赫兹的光辉。
Am Surg. 2023 May;89(5):2145-2149. doi: 10.1177/00031348211060463. Epub 2022 Jan 26.
6
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.镥 177-PSMA-617 治疗转移性去势抵抗性前列腺癌。
N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23.
7
An Improved At-Labeled Agent for PSMA-Targeted α-Therapy.一种改良的 PSMA 靶向 α 治疗放射性配体药物。
J Nucl Med. 2022 Feb;63(2):259-267. doi: 10.2967/jnumed.121.262098. Epub 2021 Jun 4.
8
Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine.治疗学：利用分子成像和治疗来影响患者管理并确保核医学的未来。
J Nucl Med. 2020 Mar;61(3):311-318. doi: 10.2967/jnumed.118.220665. Epub 2020 Jan 10.
9
Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms.使用 PSMA 靶向放射性示踪剂对非前列腺癌进行成像：基本原理、当前领域状况和行动呼吁。
J Nucl Med. 2018 Jun;59(6):871-877. doi: 10.2967/jnumed.117.203570. Epub 2018 Mar 15.
10
Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors.镥[177Lu]奥曲肽治疗中肠神经内分泌肿瘤的3期试验
N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.
Zotero 插件